News
RESMAIN: Resminostat maintenance in advanced-stage mycosis fungoides or Sézary syndrome
6+ hour, 41+ min ago (308+ words) All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit…...
DIRECT: Prognostic value of PV-supported ctDNA MRD in LBCL
2+ week, 5+ day ago (267+ words) All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit…...
GO29781 phase I/II subgroup analysis: Mosunetuzumab in older patients with R/R B-NHL
3+ week, 1+ day ago (325+ words) All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit…...
SWOG S1826 3-year follow-up: N-AVD vs BV-AVD in adolescents with AS cHL
1+ mon, 9+ hour ago (330+ words) All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit…...
SEQUOIA arms A and B: 6-year follow-up results from ASH 2025
1+ mon, 1+ day ago (341+ words) All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit…...
5-year follow-up: Mosunetuzumab in patients with heavily pretreated R/R FL
1+ mon, 2+ week ago (320+ words) All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit…...
Pirtobrutinib approved by Health Canada for the treatment of R/R MCL and CLL/SLL
1+ mon, 2+ week ago (258+ words) All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit…...